Research Associate

Research Interests

• Understanding the function(s) of GREB1 through discovery of its interactome
• Developing strategies for multiplexing single-cell sequencing
• and much, much more

• The impact of genetic modifications on tumour initiation and progression in mouse models of ovarian cancer
• Responsible for managing and maintaining  transgenic mouse lines
• Managing the Ottawa Ovarian Cancer Tissue Bank (overseen by Dr. Vanderhyden), which involves collecting and processing ovarian tumour tissue and maintaining corresponding records

Postdoctoral Fellow

Research Interests

• Role of the WNT signalling pathway in ovulatory wound repair
• Determining the role of Smarca4 in initiation of small cell carcinoma of the ovary (SCCOHT)
• Generating a mouse model of SCCOHT
• Role of the Hippo signalling pathway in ovarian cancer

Postdoctoral Fellow

Research Interests

• Enhancing ovarian cancer immunogenicity
• Modification of oncolytic viruses to improve efficacy in ovarian cancers
• Development and testing of novel immune therapies in models of ovarian cancer
  
  

• Defining the roles of SMARCA4 and SMARCA2 in ovarian function and fertility

• Why ovulation is a risk factor for ovarian cancer
• How ovarian stem cells are regulated during ovulatory wound repair
• How TGFβ1 regulates ovarian stem cells

• The role of BRCA1 loss in the initiation of ovarian cancer
• Determining why ovulation contributes to the risk of ovarian cancer
• Identifying novel therapeutic targets using a spontaneously transformed model of ovarian cancer

• The role of FGL2 in in vitro models of placental development
• Linking the roles of SNF2L(Smarca1) and FGL2 in reproductive tissues
• Investigating how aberrant levels of FGL2 may be involved in the pathology of preeclampsia 

• Cancer cell plasticity
• Transcriptional dynamics of the epithelial-mesenchymal transition in ovarian cancer
• Computational methods for the analysis of high-throughput genomics data

MD-PhD Candidate

Research Interests

• The function of GREB1 in ovarian cancer progression in estrogen-dependent and -independent models
• The clinical relevance of GREB1 as a potential biotherapeutic target

• Understanding the tumour microenvironment in ovarian cancer
• Investigating the role of FGL2 in ovarian cancer progression
• Developing novel immunotherapies for treatment of ovarian cancer

• The function of transglutaminase 2 (TG2) in ovarian cancer progression and chemoresistance
• Establishing the feasibility of novel TG2 inhibitors in the treatment of ovarian cancer